Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Deloitte
Citi
Accenture
Dow
Covington
Colorcon
Healthtrust

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMACETAXINE MEPESUCCINATE

« Back to Dashboard

Clinical Trials for Omacetaxine Mepesuccinate

Trial ID Title Status Sponsor Phase Summary
NCT00002574 Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
NCT00003239 Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003239 Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed M.D. Anderson Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003694 Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Omacetaxine Mepesuccinate

Condition Name

Condition Name for Omacetaxine Mepesuccinate
Intervention Trials
Chronic Myeloid Leukemia 3
Chronic Phase Chronic Myelogenous Leukemia 2
Leukemia 2
Chronic Myelogenous Leukemia, BCR-ABL1 Positive 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Omacetaxine Mepesuccinate
Intervention Trials
Leukemia, Myeloid 9
Leukemia 9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8
Leukemia, Myeloid, Chronic-Phase 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Omacetaxine Mepesuccinate

Trials by Country

Trials by Country for Omacetaxine Mepesuccinate
Location Trials
United States 30
France 3
India 2
Singapore 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Omacetaxine Mepesuccinate
Location Trials
Texas 8
New York 4
Indiana 3
Massachusetts 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Omacetaxine Mepesuccinate

Clinical Trial Phase

Clinical Trial Phase for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Phase 2 9
Phase 1/Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Completed 8
Recruiting 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Omacetaxine Mepesuccinate

Sponsor Name

Sponsor Name for Omacetaxine Mepesuccinate
Sponsor Trials
National Cancer Institute (NCI) 5
ChemGenex Pharmaceuticals 4
Teva Branded Pharmaceutical Products, R&D Inc. 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Omacetaxine Mepesuccinate
Sponsor Trials
Industry 11
NIH 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Army
Fish and Richardson
Moodys
Argus Health
Medtronic
US Department of Justice
Express Scripts
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.